156 related articles for article (PubMed ID: 38030799)
1. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
3. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
4. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
[TBL] [Abstract][Full Text] [Related]
5. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
[TBL] [Abstract][Full Text] [Related]
6. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
9. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
10. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
11. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
13. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
15. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
17. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
19. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
